Physician profile
Michael Urig
NPI 1750386934
$1,541.97
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.00 · 2020: $28.51 · 2021: $48.80 · 2022: $689 · 2023: $591 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.61 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $240.89 | 2022-2023 | Gelpoint V-Path |
| Organon LLC | $214.64 | 2021-2024 | Nexplanon |
| Gynesonics, INC. | $163.93 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $159.26 | 2020-2024 | Aptima, Myosure Tissue Removal Device, Acessa Provu System |
| Abbvie INC. | $127.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.13 | 2022-2023 | |
| Astellas Pharma US INC | $65.05 | 2023 | Veozah |
| Mayne Pharma Commercial LLC | $62.70 | 2023 | |
| Channel Medsystems, INC. | $60.59 | 2023 | |
| Millicent US INC | $57.93 | 2023-2024 | Femring, Intrarosa |
| Myovant Sciences INC. | $48.60 | 2022 | |
| Minerva Surgical, INC | $42.95 | 2019-2023 | |
| Coopersurgical, INC. | $30.25 | 2019-2023 | Paragard T 380a |
| Daiichi Sankyo INC. | $28.07 | 2022 | |
| Avion Pharmaceuticals | $25.50 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.91 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $21.00 | 2023 | Seglentis |
| Covidien LP | $20.55 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $17.32 | 2023 | Vivjoa |
| Boston Scientific Corporation | $16.98 | 2022 | |
| Shield Therapeutics INC | $16.62 | 2023 | |
| Allergan, INC. | $14.74 | 2019 | |
| Therapeuticsmd, INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Urig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.